Adicet Bio Gets Fast Track Designation For ADI-001 In Refractory Systemic Lupus Erythematosus
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 05 2025
0mins
Source: Business Insider
FDA Fast Track Designation: Adicet Bio, Inc. received Fast Track Designation from the FDA for its treatment ADI-001 targeting refractory systemic lupus erythematosus (SLE) with extrarenal involvement.
Ongoing and Future Studies: The company is currently enrolling patients in a Phase 1 study for lupus nephritis and plans to initiate enrollment for additional autoimmune conditions in early 2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
